ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Mortality"

  • Abstract Number: 0696 • ACR Convergence 2022

    The Mortality Trends Related to SLE in the United States – A 20-year Analysis (2001-to 2020) from the WONDER Database

    Ikwinder Preet Kaur1, Harjot Jagdey2, hasan Mirza3, Waqar Mughal4 and Pankaj Bansal5, 1Rutgers/Monmouth Medical Center, Long branch, NJ, 2BronxCare Hospital, Bronx, NY, 3Berkshire Medical Center, Pittsfield, MA, 4DHQ teaching hospital, Gujrat, Pakistan, 5Mayo Clinic, Eau Claire, WI

    Background/Purpose: SLE is an autoimmune rheumatic disease that contributes to increased morbidity and mortality due to multi-organ involvement, infections, and accelerated atherosclerosis leading to cardiovascular…
  • Abstract Number: 1667 • ACR Convergence 2022

    Pre-existing Rheumatoid Arthritis Patients Initiating Immune Checkpoint Inhibitors for Cancer Treatment: A Comparative Cohort Study Investigating RA Flare and Mortality

    Kaitlin McCarter1, Taylor Wolfgang1, Senada Arabelovic1, Xiaosong Wang1, Kazuki Yoshida1, Emily Banasiak1, Grace Qian1, Emily Kowalski1, Kathleen Vanni1, Nicole LeBoeuf1, Elizabeth Buchbinder1, Lydia Gedmintas1, Lindsey MacFarlane1, Deepak Rao1, Nancy Shadick1, Ellen Gravallese2 and Jeffrey Sparks3, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 3Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: For patients with pre-existing RA, immune checkpoint inhibitors (ICIs) for cancer treatment may trigger RA flares or other immune-related adverse events. Underlying altered immunity…
  • Abstract Number: 0711 • ACR Convergence 2022

    Improvement in Excess Mortality in Patients with Rheumatoid Arthritis over the Last Two Decades: A Danish Population-based Matched Cohort Study

    Bolette Soussi1, Kirsten Duch1, René Cordtz1, Christian Bork2, Salome Kristensen1, Erik Schmidt2, Jesper Lindhardsen3 and Lene Dreyer1, 1Center of Rheumatic Research Aalborg, Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, 2Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark, 3Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark

    Background/Purpose: Results from previous studies investigating mortality trends in patients with rheumatoid arthritis (RA) have been inconsistent, most likely due to varying cohort sizes and…
  • Abstract Number: 1668 • ACR Convergence 2022

    Rheumatic Toxicities of Immune Checkpoint Inhibitors Predict Favourable Tumour Responses in Patients with Advanced Melanoma

    Alana Bruce1, Alexander M Menzies2, Georgina V Long2, Brian Fernandes3 and Fredrick Joshua4, 1Macquarie University, Balaclava, Victoria, Australia, 2Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia, 3Royal Prince Alfred Hospital, Sydney, Australia, 4Macquarie University, Integrated Specialist Medical Care, Sydney, Australia

    Background/Purpose: To estimate the frequency of rheumatic toxicities of immune checkpoint inhibitors (ICI) presenting as de novo or exacerbations of pre-existing rheumatic disease in patients…
  • Abstract Number: 0721 • ACR Convergence 2022

    Inflammatory Rheumatic Disease and the Risk of Death Related to Coronavirus Disease-19 (COVID-19): An Analysis of the UK Biobank with Stratification by Sex

    Ashley Archer1, Ruth Topless2, Angelo Gaffo1, Nicola Dalbeth3, Lisa Stamp4, Philip Robinson5 and Tony Merriman2, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Otago, Dunedin, New Zealand, 3University of Auckland, Auckland, New Zealand, 4University of Otago, Christchurch, New Zealand, 5School of Clinical Medicine, University of Queensland, Brisbane, Australia

    Background/Purpose: There is increasing evidence that rheumatoid arthritis (RA) is a risk factor for death related to COVID-19, however data on the risk of death…
  • Abstract Number: 1757 • ACR Convergence 2022

    The Independent Impact of Gout on Mortality and Risk of Coronary Heart Disease Among Women – a Prospective Cohort Analysis of Women over 34 Years

    Chio Yokose1, natalie mccormick1, na lu2, amit johi3, Gary Curhan4 and Hyon Choi5, 1Massachusetts General Hospital, Boston, MA, 2Arthritis Research Canada, Boston, MA, 3Regeneron, Boston, MA, 4Brigham and Women's Hospital, Boston, MA, 5MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA

    Background/Purpose: The disease burden of female gout has increased in recent years.1 However, there remains a paucity of data on female gout, despite it being…
  • Abstract Number: 0764 • ACR Convergence 2022

    No Impact of Prior DMARD Exposures on Mortality in US Veterans with Cancer Treated with Immune Checkpoint Inhibitors

    Tawnie Braaten1, Brian Sauer2, Gary Kunkel3, Jessica Walsh3, Jorge Rojas4, Bryant England5, Joshua Baker6 and Grant Cannon7, 1University of Utah Hospitals and Clinics and VA Salt Lake City Health Care System, Salt Lake City, UT, 2Salt Lake City VA/University of Utah, Salt Lake City, UT, 3University of Utah, Salt Lake City, UT, 4George E. Wahlen Department of Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, 5University of Nebraska Medical Center, Omaha, NE, 6University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, 7Salt Lake City VA, Salt Lake city

    Background/Purpose: Immune checkpoint inhibitor (ICI) use for the treatment of multiple cancers continues to expand. Data on ICI treatment in autoimmune disease is limited as…
  • Abstract Number: 1845 • ACR Convergence 2022

    Mortality Prognostic Factors of Critically Ill Patients with Systemic Autoimmune Diseases Admitted in a Medical Intensive Care Unit: A 20-year Cohort Study

    Pamela Doti1, Ana Luisa Cunha2, Armin Quispe Cornejo3, Ángela Nieto González1, Andre Matos1, Pedro Guevara Hernández1, Pedro Castro Rebollo1 and Gerard Espinosa Garriga1, 1Hospital Clínic, Barcelona, Spain, 2Hospital Senhora da Oliveira, Guimarães, Porto, Portugal, 3Erasme Hospital, Brussels, Belgium

    Background/Purpose: To describe the clinical characteristics of a 20-year cohort of patients with systemic autoimmune diseases (SAD) admitted to a medical intensive care unit (ICU)…
  • Abstract Number: 0828 • ACR Convergence 2022

    Impact of Hospitalization on Clinical Outcomes in Patients with Connective Tissue Disease-associated Interstitial Lung Disease

    Navneet Kaur1, Xianhong Xie2, Anna Korogodina3, Krystal L. Cleven4, Bibi Ayesha5 and Anand Kumthekar6, 1Touro University Medical Group, Sacramento, CA, 2Department of Epidemiology & Population Health/Albert Einstein College of Medicine, Bronx, NY, 3Department of Medicine, Montefiore Medical Center-Wakefield/Albert Einstein College of Medicine, Bronx, NY, 4Division of Pulmonary Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, 5Montefiore Medical Center, Tarrytown, NY, 6Division of Rheumatology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY

    Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and mortality in patients with connective tissue disease (CTD). The aim of our study…
  • Abstract Number: 1871 • ACR Convergence 2022

    Hospitalization Outcomes for Acute Myocardial Infraction and Acute Heart Failure in Patients with Idiopathic Inflammatory Myopathies (IIM) from 2016-2019 National Inpatient Sample (NIS)

    Zi Ying Li1, Siyi Huang2, Kevin Xi3, Deepan Dalal4 and Anthony Reginato5, 1Roger Williams Medical Center, Providence, RI, 2UCSF Fresno, Fresno, CA, 3Brown University, Providence, 4Brown University School of Medicine, Providence, RI, 5Brown University, Providence, RI

    Background/Purpose: Cardiovascular disease was encountered in 15% of hospital admission from 2016-2017 for patients with idiopathic inflammatory myopathies (IIM) based on the National Inpatient Sample…
  • Abstract Number: 0101 • ACR Convergence 2022

    Twenty-five Years of Mortality Data in Those with Lower Extremity Osteoarthritis: The Role of Socioeconomic Status

    Cara Murphy1, Rebecca Cleveland1, Amanda Nelson2, Yvonne Golightly3 and Leigh Callahan4, 1University of North Carolina, Chapel Hill, NC, 2University of North Carolina at Chapel Hill, Chapel Hill, NC, 3University of Nebraska Medical Center, Omaha, NE, 4University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC

    Background/Purpose: The purpose of this study is to explore the relationship between socioeconomic status (SES) measures (income, professional employment, block group poverty level, education level,…
  • Abstract Number: 1055 • ACR Convergence 2022

    Associations of Potential Risk Factors with Severe Outcomes in Scleroderma Renal Crisis: Results from a Single Center Study

    Alex Luta1, Saloni Godbole1 and Virginia Steen2, 1Medstar Georgetown University Hospital, Washington, DC, 2Georgetown University School of Medicine, Washington, DC

    Background/Purpose: Scleroderma Renal Crisis (SRC) is a severe and life-threatening complication of Systemic Sclerosis (SSc). Given the rare nature of SSc, it is challenging to…
  • Abstract Number: 1873 • ACR Convergence 2022

    Relationship Between Baseline Characteristics of Rheumatoid Arthritis and Types of Mortality: Study of Cohort Followed Prospectively

    Cristina Corrales1, Fabricio Benavides Villanueva1, Ivan Ferraz Amaro2, Nuria Vegas Revenga3, Virgi Portilla4, Ricardo Blanco5, Miguel Ángel González-Gay6 and Alfonso Corrales4, 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, 3Hospital Galdakao- Usansolo, Galdakao, Spain, 4Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 5Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 6Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

    Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk of mortality mainly due to cardiovascular (CV) events, infections and malignancies. The relationship between the…
  • Abstract Number: 0106 • ACR Convergence 2022

    A Systematic Review of Racial and Ethnic Disparities in Disease Related Outcomes Among Patients with SLE

    Teresa Semalulu1, Keerthana Pasumarthi1, Kevin Zhao1, Rauda AlDhaheri1, Nadine Akbar2, KAREN BEATTIE1 and KONSTANTINOS TSELIOS3, 1McMaster University, Hamilton, ON, Canada, 2Humber River Hospital and University of Toronto, Toronto, ON, Canada, 3McMaster University, Population Health Research Institute, Hamilton, ON, Canada

    Background/Purpose: Racialized patients and ethnic minorities have worse outcomes in SLE. This is likely related to a complex interplay between genetic and non-genetic factors. Numerous…
  • Abstract Number: 1057 • ACR Convergence 2022

    Usefulness of REVEAL 2.0 Score as a Prognosis Tool of All-Cause Pulmonary Hypertension in Systemic Sclerosis Patients: A Multicentric Study

    Ivette Casafont-Solé1, Laura Calvo2, Anne Riveros-Frutos3, Carlos De la Puente Bujidos4, Pau Alcubilla5, Lourdes Mateo1 and Ivan Castellví6, 1Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 2Hospital Universitario Ramon y Cajal, Madrid, Spain, 3Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, 4Ramon y Cajal University Hospital, Madrid, Spain, 5Hospital Clínic de Barcelona, Barcelona, Spain, 6Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain

    Background/Purpose: Pulmonary arterial hypertension (PAH) leads to a progressive right heart failure and death.PAH is a leading cause of death in Systemic Sclerosis (SSc). To…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology